GlobeNewsWire
03 Jun 2026, 13:45 UTC · 15w ago
Verdict
Headline takes no side. We score MAIA +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 84% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish
The FDA has cleared MAIA Biotechnology to open U.S. enrollment for the expansion of the Phase 2 THIO-101 trial of ateganosine for advanced non-small cell lung cancer (NSCLC).
More positive than 92% of claims this week
Additional data from the THIO-101 expansion studies may be used to support a filing for FDA Accelerated Approval.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More positive than 85% of claims this week
MAIA is concurrently enrolling patients in a pivotal Phase 3 trial (THIO-104) involving up to 300 third-line NSCLC patients.
More positive than 76% of claims this week
The FDA previously granted Fast Track designation to ateganosine in July 2025.
More positive than 61% of claims this week
MAIA has updated its IND to include improved manufacturing protocols, new manufacturers, and revised formulation and storage conditions.
More positive than 48% of claims this week
Which stocks this story touches
More positive than 84% of ticker scores this week
Received FDA clearance to open U.S. enrollment for a Phase 2 trial expansion and has a Fast Track designation for its lead candidate.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
−1.1%
Price is moving against the score
$1.33 vs $1.35 close before publication (Jun 2) · not market-adjusted
MAIA chart →